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Abstract: Asthma and allergy incidence continue to increase globally. We have made significant strides in
treating disease, but it is becoming more apparent that we need to advance our knowledge into the origins
of asthmatic disease. Much recent work has indicated that microbiome composition influences immune
regulation and that multiple health care factors have driven a loss in microbiome diversity in modern
human populations. Evidence is growing of microbiota-driven influences on immune development, asthma
susceptibility, and asthma pathogenesis. The focus of this review is to highlight the strides the field has
made in characterizing the constituents of the human gastrointestinal microbiota, such as Helicobacter
pylori, other members of the neonatal intestinal microbiota, and microbial peptides and metabolites
that influence host immunity and immune response to allergens. As we delve further into this field of
research, the goal will be to find actionable and clinical interventions to identify at-risk populations
earlier to prevent disease onset. Manipulation of the host microbial community during infancy might be
an especially promising approach.
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Abstract   31 
Asthma and allergy incidence continue to increase globally. We have made significant strides in 32 
treating disease, but it is becoming more apparent that we need to advance our knowledge into 33 
the origins of asthmatic disease. The evidence of microbiota-driven influences on immune 34 
development, asthma susceptibility, and asthma pathogenesis is mounting. The focus of this 35 
review is to highlight the strides the field has made in characterizing the constituents of the 36 
human gastrointestinal microbiota such as Helicobacter pylori, other members of the neonatal 37 
intestinal microbiota, and microbial peptides and metabolites that influence host immunity and 38 
immune response to allergens. As we further delve into this field of research, the goal will be to 39 
find actionable and clinical interventions to identify at-risk populations earlier to prevent disease 40 
onset. Manipulation of the host microbial community during infancy may be an especially 41 




1. Introduction 46 
 47 
Asthma is a chronic inflammatory condition of the lungs that occurs worldwide. Asthmatic 48 
symptoms result from airway obstruction due to inflammatory responses to certain triggers, most 49 
commonly environmental antigens; multiple cell types and immunological mediators are 50 
involved in the pathological processes.1 It is estimated that more than 300 million people suffer 51 
from asthma, with a burden that has increased substantially over the past several decades.1 52 
Several risk factors have been implicated in asthma susceptibility including host genetics, 53 
specific environmental exposures, obesity, and respiratory infections during early life. Attention 54 
is now turning to the role of the human microbiome in asthma pathogenesis and protection.  The 55 
microbiome, a community of organisms including bacteria, archaea, fungi and viruses that live in 56 
and on us is now recognized as an important contributor of host homeostasis via physiological, 57 
immunological, and metabolic regulation. With improved analytical tools, there has been 58 
increasing focus on elucidating the mechanisms by which the constituent microbiota impacts 59 
both homeostasis and disease susceptibility.  An important frontier is to identify potential 60 
therapies to improve human health, prevent the onset of microbiota related diseases, and to 61 
identify appropriate therapies.  Although these topics are now being studied in relation to 62 
obesity, diabetes, inflammatory bowel disease (IBD), and neoplasia, in this review we will focus 63 
on asthma and related allergic disorders.  We will consider the overall biology of the 64 
microbiome, its role in immunological development, and how perturbations are affecting the 65 
asthmatic diathesis. Finally, we will consider how the emerging knowledge can be harnessed for 66 
improved prevention and therapies 67 
 68 
 69 
2. Biological characteristics of the human microbiome. 70 
 71 
Understanding the biology of the microbiome is a starting point for considering its relationship to 72 
asthma. There are seven critical characteristics. First, the human microbiome is niche-specific. In 73 
each anatomical locale that harbors a microbiome, the microbial populations differ.  These 74 
populations are both unique and overlapping, and there is evidence for interactions between 75 
them.2 Even niches that once were considered to be ‘sterile,’ are being shown to contain resident 76 
microbial populations, including the esophagus, stomach, and lower respiratory tract.3 Second, in 77 
all niches, there are both persistent and transient organisms; although the definitions and 78 
boundaries vary, and are biologically relevant, the emphasis of investigation has been on 79 
understanding the persistent microbiota-the organisms that may endure for years, decades, or 80 
life.  81 
 82 
Third, across individuals, the microbiota are taxonomically highly diverse. This diversity has 83 
been best studied in relation to bacterial populations, but also is present for fungi and viruses. At 84 
a functional level, the overall outlines are more conserved, since, for example, all bacteria use 85 
stereotypic mechanisms to process energy, build cell walls, reproduce, and move, but 86 
nevertheless there is enormous variation as well.  Fourth, the microbiota in aggregate are 87 
numerous. Current estimates are that the number of bacterial and human cells in our bodies are 88 
roughly equivalent with residential viruses perhaps ten-fold greater. At a genetic level, the 89 
differences are greater. In comparison to the current view of 23,000 human genes, each of us 90 
carries from 2-20 million unique bacterial genes, all subject to regulatory pathways.2  91 
 92 
Five, the microbiome is ancient. All animals have their own characteristic microbiomes. Among 93 
vertebrates, the phylogenies of the microbiota parallel those of their hosts. This provides strong 94 
evidence for the overall vertical transmission of the microbiome and also supports the concept of 95 
co-evolution of host and microbial population.4  In studies of primates, the congruent 96 
phylogenies, at the aggregate level, and for particular marker taxa, is consistent with the overall 97 
view, and provides a milestone of at least 8 million years of congruence.5 Sixth, the essential 98 
structure of the microbiome is acquired early in life. In the womb, human life begins in a mostly 99 
sterile environment; there is no reproducible evidence for an in utero persistent microbiome. 100 
Exposure to microbes begins when the water breaks, the first step in the introduction and transfer 101 
of maternal microbiota to the infant. There are multiple parallel and redundant routes involving 102 
colonizing the gastrointestinal tract, mouth, and skin. The population structure of the infantile 103 
microbiome develops gradually and progressively, and by the age of three, in the GI tract at 104 
least, has taken on the major characteristics of the adult microbiota.6 105 
 106 
Seven, the microbiota is interactive with host physiology. Studies focusing on immunity, 107 
metabolism, and cognition all provide evidence for strong microbiota effects on all these 108 
characteristics, with reciprocal properties as well.7, 8 It is this property, in the context of the 109 
above characteristics, that require attention in relation to asthma and allergic disorders. 110 
 111 
3. The human microbiome is changing. 112 
 113 
With the advancements in economic and social development over the past two centuries have 114 
come new pressures on the human microbiome, accelerating in the past 50 years. Clean water, 115 
with all of its important benefits, limits the interpersonal spread of commensal organisms. 116 
Cesarean sections, now occurring in more than half of pregnancies in some populations, and 25-117 
33% in many others, bypasses the original microbial seeding that occurs during natural delivery. 118 
Formula feeding, substituting for human breast milk, does not contain the micronutrients that 119 
evolved over the eons to nourish ancestral microbes. The use of anti-bacterial agents in foods, 120 
and in topical applications impacts the developing microbiome. Most importantly, human 121 
children all over the world are receiving multiple courses of potent antibiotics, often at high 122 
dose, over the early years of life. All of these practices have been predicted to affect microbial 123 
composition and thus host physiology.9, 10  Based on the largely vertical transmission of the 124 
microbiota, it was predicted that that loss of diversity would be cumulative across human 125 
generations.11  126 
 127 
Unfortunately, there is increasing evidence that these predictions were correct. Studies of human 128 
populations at differing levels of socio-economic advancement have shown the highest 129 
microbiota diversity in populations with limited access to modernization and lowest diversity in 130 
peoples in industrialized countries.12, 13 These trends are irrespective of continent of origin, diet, 131 
and ethnicity, but point to modernization/urbanization and all of its accompanying trends as the 132 
key factor. Recent studies of immigrants to the USA from developing countries provide evidence 133 
of loss of diversity in real time.14 134 
 135 
These trends have been encapsulated in the Theory of the Disappearing Microbiota9, 10 which has 136 
two major tenets: (i), changed human ecology has altered transmission and maintenance of 137 
ancestral microbes, which affects the composition of the microbiota, and (ii), the microbes, both 138 
good and bad, usually acquired early in life are especially important, since they affect a 139 
developmentally critical stage. Since the interaction of the microbiota with human physiology is 140 
so profound, this theory predicts that the changed microbiota affects host physiological 141 
functions,15 with immunity being particularly relevant to asthma. Although the potential for 142 
antibiotics to lead to important ecological effects has been well-recognized, most of the focus has 143 
been on the development of antibiotic resistance. Although resistance is quite important, it 144 
probably represents only the tip of the iceberg (Figure 1), in which the larger mass, currently 145 
hidden from plain view is the effects on microbiome composition and the subsequent 146 
physiological and clinical consequences. These views concern exposure to and acquisition of 147 
human-specific ancestral microbiota, and can be contrasted with a more general construct, “the 148 
hygiene hypothesis,” which largely focuses on environmental exposures, including to 149 
domesticated animals.16  150 
 151 
4. Helicobacter pylori as an indicator organism and protagonist. 152 
 153 
Initially identified in the 19th century, the organisms that now are called Helicobacter pylori were 154 
first isolated from human gastric biopsies in 1983.17 There is considerable evidence that H. pylori 155 
is ancient,18 having colonized our ancestors at least 100,000 years ago.19  Based on its 156 
ancientness, its presence in all human populations in which it has been studied, its acquisition in 157 
early life and life-long persistence, H. pylori clearly can be considered as a member of the human 158 
gastric microbiota, and when present is usually the dominant member of the gastric microbiota.20  159 
However, it is progressively disappearing from human populations, reflecting many of the trends 160 
mentioned above.  As such, it is possible to associate its presence or absence with human 161 
diseases. First discovered as a pathogen in the 1980’s, the presence of H. pylori is clearly linked 162 
to the risk of developing peptic ulcer disease and adenocarcinoma of the stomach.21  However, 163 
its absence has been linked to esophageal diseases including Gastro-esophageal Reflux Disease 164 
(GERD), Barrett’s Esophagus, and adenocarcinoma of the esophagus and the adjacent G-E 165 
junction.22 Similarly, its absence has been linked in multiple large, blinded, epidemiological 166 
studies, with the risk of developing childhood-onset asthma.23-25 H. pylori strains may be divided 167 
into those possessing the cag island with host-interactive genes or not.26 The cag+ strains are 168 
those that are most strongly related to risk of disease (ulcers and cancer) as well as protection 169 
from disease (esophageal diseases, asthma), which is consistent, since this is the subset of strains 170 
with the strongest host interactions.26 The epidemiologic studies also found parallel relationships 171 
with hay fever and cutaneous allergies, two disorders independently linked with asthma.23 172 
Results of these epidemiologic studies generate the hypothesis that gastric H. pylori colonization 173 
is protective against asthma and related disorders, and that the rise of asthma is at least in part 174 
fueled by the loss of this ancestral gastric colonizer, with loss of protective immunological 175 
functions (to be discussed below). 176 
 177 
5. Role of the microbiome in immune development (evidence in humans and in model 178 
systems.  179 
 180 
The microbiota is a known regulator of immune development, cell differentiation, and cell 181 
function. Increasing evidence over the past decade has shown that specific bacterial strains as 182 
well as defined mixtures of bacteria can elicit predicted immune phenotypes.8, 27-29 183 
 184 
Intestinal 185 
Specific members of the murine microbiome, some of which are shared with humans, have 186 
stereotypical interactions with immunological effector cells. Specific clades of clostridia species 187 
isolated from human stool samples can induce colonic T regulatory cells (Tregs) in a murine 188 
model.27 Segmented filamentous bacteria (SFB; Candidatus Savagella) are members of murine 189 
microbiota that elicit Th17 differentiation in the intestinal tract of mice.28 Helicobacter hepaticus 190 
induce RORgt+ T regulatory cells that suppress Th17 cell function; in the absence of these 191 
induced Tregs, H. hepaticus potentiates Th17-driven colitis.30  A mixture of 11 human 192 
commensal bacterial strains  has been identified that induced IFNg production by CD8+ T cells 193 
in the mouse colon; these had effector functions useful in anti-pathogen and anti-tumor 194 
responses.29 The above taxa provide examples of how well-characterized bacterial commensals 195 
can drive immune differentiation and translate to actionable phenotypes within the intestinal 196 
environment.  197 
 198 
Gastric 199 
H. pylori, an ancient, persistent and vertically transmitted constituent of the gastric microbiota, is 200 
among the best studied examples of a highly immunomodulatory bacterium with potent effects 201 
on asthma risk and severity. Not only do large epidemiological studies point to an inverse 202 
association of H. pylori with allergic asthma, especially in children and young adults;11, 24, 25, 31 203 
there also is substantial experimental data from mouse models to provide evidence for causality. 204 
The gold standard mouse models of allergen-induced airway inflammation and hyper-205 
responsiveness entail the sensitization, and subsequent challenge (both ideally performed 206 
intranasally or intratracheally to mimic the dominant route of exposure in humans) of mice with 207 
potent allergens such as ovalbumin or house dust mite extract. In such experimental models, 208 
chronic infection with H. pylori efficiently reduces the markers of allergic asthma including: (i), 209 
excessive pulmonary Th2 responses and associated high levels of the Th2 cytokines IL-5 and IL-210 
13; (ii), aberrantly high systemic levels of allergen-specific IgE; 32, bronchoalveolar eosinophilia; 211 
and (iv), goblet cell hyperplasia and the associated excessive mucus production.33 Lung function 212 
is restored as well in H. pylori-infected mice as determined by methacholine challenge assay.33 213 
In line with observations in humans, which highlighted particularly strong inverse associations of 214 
H. pylori with early-onset asthma,11, 31 the experimental data suggest that neonatal infection with 215 
H. pylori, but not infection of adult mice, results in protection against allergic asthma signs and 216 
severity.33 Several prerequisites of protection have been identified in addition to the early-life 217 
window of opportunity, which may be considered as the “neonatal tolerance window”.34, 35 In 218 
particular, an immunomodulatory molecule that all H. pylori strains produce, the so-called 219 
vacuolating cytotoxin, has been implicated in H. pylori’s asthma-protective effects.36-38 VacA-220 
deficient isogenic mutants fail to protect against allergic asthma in neonatal infection models,38 221 
and VacA purified from culture supernatants of H. pylori is very potent at suppressing allergic 222 
asthma in prophylactic settings.37  More recent tracing experiments have shown that VacA 223 
targets different myeloid cells in the gastric mucosa, generating a tolerogenic environment 224 
characterized by high levels of immunoregulatory cytokines such as IL-10 and TGF-ß (Figure 225 
2).36 As VacA is not only required for the protective effects of live infection, but sufficient to 226 
prevent allergy on its own, it deserves to be investigated further and developed for possible 227 
interventional application in humans. 228 
 229 
H. pylori has not only been inversely linked to allergic asthma, but also appears to have strong 230 
immunomodulatory and beneficial effects in other settings of allergic and chronic inflammatory, 231 
and possibly autoimmune disorders. In particular, patients with either of the two major forms of 232 
inflammatory bowel disease, Crohn’s disease and ulcerative colitis, harbor H. pylori at much 233 
lower rates than the general population.39 In mouse models of IBD, H. pylori infection and 234 
regular administration of H. pylori extracts protects against severe disease as determined by 235 
histological analysis, and other readouts.40 Among allergic disorders, food allergy to ovalbumin 236 
allergen and peanut extract has been shown to be alleviated by live H. pylori, its extract as well 237 
as purified VacA.41 One study has shown an inverse association of H. pylori infection with 238 
multiple sclerosis, and has provided experimental evidence in the mouse model of MS, 239 
experimental autoimmune encephalomyelitis (EAE), for protective effects of H. pylori on the 240 
CNS findings associated with this disease.42 Atopic dermatitis is another allergic disease 241 
manifestation with which H. pylori has been inversely linked in humans,43, 44 as well as skin 242 
sensitivity to a panel of allergens22, but experimental data to support protective effects of the 243 
bacteria in the skin are not available. In yet another study, the presence of H. pylori, was 244 
inversely related to the diagnosis of celiac disease.45 but the direction of causality has not been 245 
confirmed. 246 
  247 
H. pylori creates a tolerogenic environment in the gastric mucosa that is at least in part driven by 248 
VacA and its interactions with the myeloid compartment.46 Recent work has shown H. pylori 249 
(expressing RFP, and thereby allowing its tracking to specific immune compartments) to interact 250 
directly with various myeloid cell populations, which are recruited to the gastric mucosa along 251 
chemokine gradients.46 At least six distinct myeloid populations with diverse functions appear in 252 
the mouse stomach upon H. pylori infection, but are virtually absent in the steady state 253 
stomach;46 of these, three are considered bona fide dendritic cells (DCs), as they express CD11c 254 
and depend on the growth factor FLT3 ligand for their differentiation from bone marrow 255 
precursors. The others are macrophages and monocytes expressing the respective lineage 256 
markers F4/80, CD64 and Ly6C, among others. RFP+ bacteria are in direct contact with all 257 
macrophage and monocyte, and some, but not all, DC lineages in the gastric lamina propria, and 258 
also encounter large numbers of eosinophils in their natural environment.46, 47 Some of these 259 
interactions have been investigated functionally using mouse strains deficient for the respective 260 
lineages. From this work, it is now clear that CD103+ DCs are required for Th1-driven immunity 261 
on the one hand, and for the recruitment to infected tissues of peripherally induced Tregs 262 
(pTregs) on the other.48 In the absence of CD103+ DCs (in BATF3-/- mice, which lack the key 263 
transcription factor driving CD103+ DC differentiation49), the priming of Th1 cells and pTregs in 264 
lymph nodes proceeds normally, but both T-cell subsets fail to upregulate expression of the 265 
chemokine receptor CXCR3, and therefore cannot traffic to the infected gastric mucosa along 266 
CXCL9 and CXCL10 chemokine gradients (Figure 2).48 The defects of BATF3-/- mice in both 267 
populations manifest in two ways: on the one hand, BATF3-/- mice are severely hypercolonized 268 
since they cannot control H. pylori48 and on the other hand, they are not protected against allergic 269 
asthma upon neonatal infection due to their functional Treg defect.37  270 
 271 
Another cell type that is emerging as playing a critical role at the interface of H. pylori with its 272 
host is the eosinophil, a cell type that has mostly been associated with Th2-driven immune 273 
responses to parasites and allergens. Eosinophils, as with other myeloid populations, are 274 
recruited to the H. pylori-infected gastric mucosa in large numbers and come in direct contact 275 
with live bacteria. This interaction does not result in H. pylori killing, despite the fact that 276 
eosinophils have potent bactericidal activity towards other gastrointestinal pathogens, such as 277 
Citrobacter rodentium.47 Rather, it appears as if eosinophils acquire immunoregulatory activity 278 
in the gastrointestinal lamina propria, at steady state and during infection, and suppress 279 
inappropriate or excessive Th1 responses to promote tissue homeostasis and control 280 
inflammation. Indeed, eosinophil-deficient mice control H. pylori more efficiently than their 281 
eosinophil-proficient counterpart, which has been attributed to their unrestricted Th1 responses.47 282 
 283 
Several studies in humans and mice have pointed to the relative strength of effector T-cell and 284 
Treg responses to H. pylori infection as a major determinant of disease risk and severity, both 285 
with in the stomach and outside. Humans with a Treg-predominant anti-H. pylori response are 286 
less likely to develop gastric ulcers than those with a Th1 or Th2 polarized effector T-cell 287 
response to the organism, and the levels of circulating H. pylori-specific Tregs, especially those 288 
producing the regulatory cytokine IL-10, are inversely associated with serum IgE levels.42, 50, 51 289 
In H. pylori-infected children, gastritis manifestations are typically much less severe than in 290 
adults, and effectively controlled by a dominant Treg response.52 These data are all in line with 291 
beneficial effects of H. pylori in childhood and adolescence, but not later in life, and implicate H. 292 
pylori-specific Tregs as mediators of asthma protection. Several lines of experimental evidence 293 
from mouse models support this idea: (i), neonatally infected mice develop much less severe 294 
gastritis upon H. pylori infection than mice exposed as adults, and never exhibit evidence of 295 
preneoplastic lesions, which are common in adult-infected animals53 ;  (ii), in asthma models, 296 
protection is limited to mice infected as neonates33 ; and 32, depletion of Tregs abrogates 297 
protection in the neonatal infection model, and the adoptive transfer of Foxp3+ Tregs is sufficient 298 
to confer protection in naïve recipients.33 The protective population of Tregs has yet to be 299 
characterized in detail using functional approaches, but appears to be pTregs rather than thymus-300 
derived, and expresses the transcription factors ROR฀t and Tbet.36, 48 H. pylori-induced pTregs 301 
are enriched in the infected mouse gastric mucosa, but traffic to and accumulate in the lungs 302 
(Figure 2). This (mis) localization is specific to neonatally infected mice and believed to 303 
underlie the protective effects of neonatal infection on pulmonary manifestations of allergic 304 
diseases.36, 48   In another murine model with experimental H. pylori challenge, colonization led 305 
to changes in gastric gene expression, immunological function and hormone secretion, and 306 
effects on the intestinal microbiota, as well as changes in pulmonary gene expression and T-cell 307 
populations, supporting the linkage with extra-gastric pathophysiology.54  308 
 309 
Skin 310 
Applied to the skin of mice,  human cutaneous commensals elicited both cytokine and T cell 311 
responses; of those, Staphylococcus epidermis was unique in its ability to induce CD8 T cells 312 
producing IL17 at the inoculation site.55 Commensal-specific T cells, both CD4+ Th17 and CD8+ 313 
Tc17 cells, are transcriptionally programmed to maintain a Type 17 anti-microbial response and 314 
a Type 2-poised response that is elicited in response to tissue inflammation, epithelial damage, 315 
and alarmins.56 This work identifies how microbiota-driven immune development plays a role in 316 
maintaining physiological homeostasis and adaptable immune responses at mucosal sites.  317 
 318 
Age, microbiota, and immunity 319 
There is strong evidence that the age of the host is an important factor contributing to the host-320 
immune axis. An important concept is that there is a critical window of development in which 321 
the microbiota regulate the immune education that cannot be meaningfully altered once that time 322 
period has elapsed.57  (Figure 3). The acquisition of host-specific microbiota at birth 323 
differentially regulates intestinal immunity; mice raised with murine microbiota were more 324 
protected against gastrointestinal pathogens than mice raised with human microbiota.58 Several 325 
lines of evidence support the view that the composition of the microbiota during early-life plays 326 
a critical role in immune phenotypes observed later in life. The maternal microbiota also plays a 327 
role in regulation of the offspring’s innate immunity,59 indicating that such development starts in 328 
utero and further points to post-natal events that regulate the immune maturation.  In an animal 329 
model, age at the time of first exposure is a major determinant of the outcome of the H. 330 
pylori/host interaction. Whereas the neonatal tolerance window closes at 7-10 days after birth in 331 
mice, it may commence well before delivery. Evidence towards this end comes from studies in 332 
which mice were exposed to H. pylori extract in utero or transmaternally during lactation.41 Such 333 
offspring showed substantial protection against allergic disease manifestations, independent of 334 
the protection status of the mother.41  335 
 336 
These concepts support the importance of further characterizing early-life host-microbiota 337 
interactions, and going forward require focus on interventions that may have lasting clinical 338 
benefits.  339 
 340 
6. The microbiome as a mediator of asthmatic disease 341 
 342 
There also is evidence to support a role for both exogenous and endogenous microbiota 343 
contributing to childhood asthma development. For example, prenatal exposure to a rural farm 344 
environment correlated with protection against atopic sensitization in children.60 In large 345 
epidemiological studies, antibiotic use during the first year of an infant’s life correlated with 346 
increased asthma risk in young children.61, 62 Similarly, in British Columbia, a period of 347 
decreased antibiotic use during the first year of life significantly correlated with reduced asthma 348 
risk. 63 There is sufficient evidence to support that antibiotic use, mode of delivery, and diet can 349 
impact composition of the human infant microbiota.64 In support of the importance of microbial 350 
exposure and susceptibility to asthma, low doses of endotoxin were protective in a murine model 351 
of house dust mite-induced airway inflammation65; in the same model, germ free mice had 352 
stronger immune responses.66 Germ-free mice have higher serum IgE levels than select pathogen 353 
free (SPF) mice. As such, germ-free mice having increased susceptibility to anaphylaxis, a 354 
phenotype that can be ablated when mice are inoculated with a diverse microbiota before 6 355 
weeks of age.67 Collectively such evidence indicates that overall, increased exposure to certain 356 
types of bacteria or their products during early life correlates with protection from asthma and 357 
allergic diseases. 358 
 359 
In the CHILD cohort in Canada, children at risk for asthma were found to have reduced 360 
abundance of the genera Lachnospira, Veillonella, Faecalibacterium, and Rothia, as well as 361 
reduced fecal acetate levels. Transfer of fecal samples from at-risk children to germ-free mice, 362 
and restoring the missing bacterial genera, reduced the asthma phenotypes in an ovalbumin 363 
model of airway inflammation.68 In a Danish prospective cohort study on asthma, an association 364 
between the human fecal microbiota composition at 1 year and asthma risk at age 5 was 365 
identified. Specifically, children born to asthmatic mothers and displaying altered microbial 366 
composition at age 1 were 13-times more likely to have asthma at age 5 than other children in the 367 
cohort.69 In the US, children at the highest relative risk of atopy and asthma had reduced 368 
abundance of Bifidobacterium, Akkermansia, and Faecalibacterium in the neonatal gut, and 369 
enrichment of the linoleic acid 12,13-diHOME, a bacterial metabolite.70 In a murine asthma 370 
model, increasing intestinal concentrations of 12,13-diHOME led to reduced pulmonary Treg 371 
abundances and increased inflammation.71  Overall, these studies have identified important and 372 
overlapping evidence of particular bacterial genera and metabolites that correlate with protection 373 
from asthma.  374 
 375 
Beyond the gastrointestinal tract, the human lung bacterial community appears to be dominated 376 
by 6 genera during the first two years of life, at which point further diversification takes place. 377 
Colonization with pathogens predicts chronic wheeze in sensitized children. In addition, children 378 
with increased abundance of Streptococcus, Hemophilus, and Moraxella in induced sputum 379 
samples had increased risk of chronic wheeze at age 5.72 Asthmatic patients were also reported to 380 
have increased diversity in the lung microbiota, but reduced biomass.73 These findings support 381 
roles of the pulmonary microbiota in influencing susceptibility to asthma, in addition to the 382 
influence of the gastrointestinal tract microbiota on asthmatic pathophysiology 383 
 384 
 385 
7. Solutions 386 
 387 
Based on the increasing evidence of microbiota roles in asthma, it is important to begin to 388 
consider specific solutions to both prevention and treatment. An obvious approach, which 389 
nevertheless must be stated, is to avoid further damage to the microbiome. Physicians and 390 
parents should juxtapose the physiological costs of antibiotic courses, formula feeding, and 391 
Cesarean section when considering their benefits in individual patients. A more accurate 392 
estimation of antibiotic benefit and risk would clearly reduce their overuse, as well as that for 393 
other medical interactions. The conversation should shift from “this might be helpful,” to “is this 394 
necessary?’ 395 
 396 
A more specific approach is to attempt to restore particular disappeared organisms to either 397 
prevent or treat asthma. The development of such approaches will ultimately require clinical 398 
trials to assess benefit and risk. All over the world, patients with asthma are taking ‘probiotics’ 399 
that can be bought over the counter or prescribed by their physician. The actual base of scientific 400 
knowledge that underpins the use of these diverse products in millions of individuals is 401 
surprisingly sparse. As above, clinical trials are needed to test their efficacy. An intriguing 402 
possibility will be to give H. pylori to children to restore this ancestral organism (Figure 4) and 403 
take advantage of its asthma- and reflux-reducing properties, and then eliminate it with 404 
antibiotics in adulthood to reduce its potential to drive gastric cancer. Clinical trials now aim to 405 
also exploit the prenatal window of opportunity.  In one trial, pregnant women and prospective 406 
mothers of at-risk offspring are being given the prebiotic inulin, to determine effects on the 407 
occurrence of atopic dermatitis as a primary end-point and early predictive readout of allergy.74 408 
A recent meta-analysis of 28 studies investigating the effects of probiotics given pre- and/or 409 
post-natally concluded that the risk of atopic dermatitis (as the earliest possible readout of atopy) 410 
could be reduced by starting probiotic treatment during gestation and continuing it through the 411 
first six months of the infant's life.75 The available mouse data suggest that live H. pylori, or its 412 
extract, might be equally or more efficient than pre- or probiotics at reducing allergy risk when 413 
given as early as possible in life. 414 
 415 
In the future, microbes that have stereotypic interactions with particular arms of human 416 
immunity will be important candidates for trials. Alternatively, microbes or chemicals 417 
(prebiotics) that have no direct effect in immunity, but which nourish or stabilize endogenous 418 
immunologically active populations, may be useful. Recent studies that have identified particular 419 
taxa68, 69 and bacterial metabolites70 associated with reduced asthma risk in human children may 420 
be especially useful. 421 
 422 
If the most beneficial organisms for asthma prevention have already largely disappeared from 423 
developed country populations, where will we obtain the organisms necessary for restoration? 424 
One solution will be to identify individuals and populations with little or no exposure to the 425 
modernizing practices, and stockpile these specimens and purified cultures for future 426 
generations. A non-governmental non-profit foundation has recently been established [The 427 
Microbiota Vault, Inc.: microbiotavault.org ] (Figure 5) to facilitate this process,76 in analogy to 428 
the Seed Vault, now in existence to preserve our precious patrimony of seeds for food 429 
cultivation. 430 
 431 
8. Conclusions  432 
 433 
A growing body of evidence is linking the microbiome—respiratory and gastro-intestinal—with 434 
the altered pathophysiology operant in asthma and related allergic disorders. Such linkage is 435 
biologically plausible, and ultimately actionable, since tools already are in existence to reshape 436 
the microbiome in desired directions.  However, much foundational work must be done to 437 
establish particular preventive and therapeutic modalities.  Nevertheless, the promise is great for 438 
curtailing the pandemic of asthma by applying the knowledge learned about microbiome-439 
immunologic interactions. Further explorations in this clinically important area will deepen our 440 
understanding of human immunology as well, with applications to other immune and auto-441 




What do we know? 446 
 We know candidate organisms identified in both the gastric mucosa (H. pylori) and 447 
intestinal tract that can confer protection in murine asthma models and correlates with 448 
protection in humans 449 
 We have begun to identify bacterial lung species, intestinal species, and metabolites that 450 
correlate with asthma or atopy.  451 
 452 
What do we still need to know? 453 
 We need to better understand how to take actionable steps to modulate the microbiota, 454 
and the windows of time at which these interventions are optimal in human hosts.  455 
 We need a greater understanding of how candidate strains of bacteria or their metabolites 456 
interact with the rest of the microbiome. In the context of an ecosystem, we need to 457 
understand how one introduced member impacts the whole.   458 
 Although there is a growing body of evidence with respect to metabolites and bacterial 459 
strains on T regulatory cells in asthmatic disease, we need to further advance our 460 
understanding of how bacteria-driven immune differentiation can alter immune responses 461 
to environmental antigens and allergens.  462 
 463 
 464 
Figure legends 465 
 466 
Figure 1. Ecological effects of antibiotic exposures.  Antibiotic resistance has long been 467 
recognized as an ecological consequence of antibiotic exposure. However, an additional 468 
hypothesis is that, like the proverbial iceberg, the disruption of the microbiome leading to 469 
clinical consequences, is the ‘inapparent’ or larger part’. Even transient antibiotic exposures, in 470 
early life or prior to adventitious infections, can lead to long-term consequences.61, 64, 77, 78 471 
Exposures of women before the birth of their children can lead to consequences in the next 472 




Figure 2. Helicobacter pylori infection is strictly local but has systemic effects at distant 477 
sites. Half of the world’s population carries Helicobacter pylori; in endemic regions with high 478 
(>80% prevalence), H. pylori transmission occurs within the first two years of life, and mostly 479 
from mother to offspring. The only reservoir of live H. pylori is the human stomach; it is not 480 
found in other tissues of the body or in the stomach in other species. H. pylori either swims 481 
freely in gastric mucus or binds to gastric epithelial cells. In experimental models, the bacteria 482 
recruit cells of myeloid origin into the gastric lamina propria, which are known to interact with 483 
live bacteria or their products, presumably through intraepithelial protrusions. VacA and the 484 
enzyme g-glutamyl-transpeptidase (GGT) are two immunomodulators that all H. pylori strains 485 
express and use to manipulate myeloid cells. Antigen-presenting cells, and in particular CD103+ 486 
DCs, migrate to the draining gastric and mesenteric lymph nodes, where they prime T-effector 487 
(mostly Th1 and Th17) and regulatory T-cell (Treg) responses. H. pylori-induced Th1 cells and 488 
Tregs substantially express the chemokine receptor CXCR3 on their surface, which allows for 489 
their trafficking to the stomach along a gradient of the CXCR3 ligands CXCL9 and 10. In the 490 
absence of CD103+ DCs, this trafficking does not happen and mice are hypercolonized. The Treg 491 
population that changes most with H. pylori colonization are peripherally induced Tregs 492 
(pTregs), distinguishable from their thymus-derived counterparts by their RORgt and Tbet, and 493 
lack of neuropilin expression. pTregs in the gastric mucosa suppress pathogen-specific Th1 494 
responses and promote persistent H. pylori colonization. Importantly, pTregs with the same 495 
profile also traffic to, and accumulate in, the lungs of infected mice, where they likely are 496 
involved in the suppression of allergen-specific Th2 and Th17 responses; pTregs strongly 497 
produce TGF-ß and IL-10.   498 
 499 
Figure 3. Early life influences on the developing microbiome affect ‘immunological tone’. 500 
The maternal microbiome interacts with the mother’s immune system, which then further shapes 501 
the microbiome; it is a continuous cycle. At birth, the maternal microbiome is transferred to the 502 
baby as well as immunological molecules (including antibodies, cytokines,  and specific 503 
metabolites). Together, these interact with innate immunity to set ‘immunological tone,’ which 504 
then affects the development of adaptive immunity. Many aspects of modern health care can 505 
perturb these relationships. 506 
 507 
Figure 4. A prediction for the medicine of the future. For well-baby visits, future pediatricians 508 
will examine both babies and their diapers. They will determine whether that infant has the ideal 509 
microbiota for their genotype and other markers. If not, they will administer the ‘missing 510 
microbes’ to optimize their health trajectory through life. Physicians will follow microbiological 511 
parameters during childhood, adjusting as necessary, to continue optimization. 512 
 513 
Figure 5. Creating a repository to preserve the ancestral microbiota. A non-profit foundation  514 
(The Microbiota Vault, Inc.; www.microbiotavault.org), has been established to develop a global 515 
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